Nicolas Guibert

Dr. Nicolas Guibert


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in Lung Cancer
Verified
Journal Article
Closed access
NGNicolas Guibert
Nicolas Guibert
MDMyriam Delaunay
Myriam Delaunay
ALAmélie Lusque
Amélie Lusque
NBNadia Boubekeur
Nadia Boubekeur
IRIsabelle Rouquette
Isabelle Rouquette
APAnne Pradines
Anne Pradines

12 February 2020 in European Respiratory Review
Verified
Journal Article
Open access
PDF file
NGNicolas Guibert
Nicolas Guibert
APAnne Pradines
Anne Pradines
GFGilles Favre
Gilles Favre
JMJulien Mazieres
Julien Mazieres
Liquid biopsy refers to the analysis of any tumour-derived material circulating in the blood or any other body fluid. This concept is particularly relevant in lung cancer as the tumour is often difficult to reach and may need an invasive and potentially harmful procedure. Moreover, the multitude of anticancer drugs and their sequential use underline the importance of conducting an iterative assessment of tumour biology. Liquid biopsies can noninvasively detect any targetable genomic alteration and guide corresponding targeted therapy, in addition to monitoring response to treatment and exploring the genetic changes at resistance, overcoming spatial and temporal heterogeneity.In this article, we review the available data in the field, which suggest the potential of liquid biopsy in the area of lung cancer, with a particular focus on cell-free DNA and circulating tumour cells. We discuss their respective applications in patient selection and monitoring through targeted therapy, as well as immune checkpoint inhibitors. The current data and future applications of liquid biopsy in the early stage setting are also investigated.Liquid biopsy has the potential to help manage nonsmall cell lung cancer throughout all stages of lung cancer: screening, minimal residual disease detection to guide adjuvant treatment, early detection of relapse, systemic treatment initiation and monitoring of response (targeted or immune therapy), and resistance genotyping.

11 March 2020 in Respirology
Verified
Journal Article
Open access
PDF file
NGNicolas Guibert
Nicolas Guibert
HSHideo Saka
Hideo Saka
HDHervé Dutau
Hervé Dutau
AS offers rapid and sustained relief of symptoms in most patients treated for malignant or benign CAO and can also be curative in itself in cases of benign tracheobronchial stenosis. In the past 30 years, this field has seen significant progress, from the misuse of vascular non‐covered metallic stents to the development of silicone airway stents with an increasingly large panel of shapes and of hybrid, partially or fully covered, SEMS customized to the airways. This study aims to offer an overview on: (i) the respective advantages and drawbacks of these two main categories of devices; (ii) the main indications for AS and the rationale behind the choice of stent in each situation; and (iii) the main promises borne from the progress made in the field in the past few years, including the development of drug‐eluting, biodegradable or patient‐specific customized AS.

1 November 2019 in Lung Cancer
Verified
Journal Article
Closed access
NGNicolas Guibert
Nicolas Guibert
GJGreg Jones
Greg Jones
JBJohn F. Beeler
John F. Beeler
VPVincent Plagnol
Vincent Plagnol
CMClive Morris
Clive Morris
JMJulien Mazieres
Julien Mazieres

7 April 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
NGNicolas Guibert
Nicolas Guibert
JMJulien Mazieres
Julien Mazieres
MDMyriam Delaunay
Myriam Delaunay
ACAnne Casanova
Anne Casanova
MFMagali Farella
Magali Farella
APAnne Pradines
Anne Pradines
Monitoring of KRAS -mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma

1 November 2016 in Journal of Thoracic Disease
Verified
Journal Article
Closed access
PDF file
NGNicolas Guibert
Nicolas Guibert
LMLaurent Mhanna
Laurent Mhanna
SDSylvain Droneau
Sylvain Droneau
GPGavin Plat
Gavin Plat
ADAlain Didier
Alain Didier
CHChristophe Hermant
Christophe Hermant
Interventional bronchoscopy has a predominant role in the management of both early and advanced-stage airway tumors. Given the very poor prognosis of lung cancer, there is a need for new tools to improve early detection and bronchoscopic treatment of endo-bronchial precancerous lesions. In more advanced stages, interventional bronchoscopy plays an important role, as nearly a third of lung cancers lead to proximal airway obstruction. This will cause great discomfort or even life-threatening symptoms related to local extension, such as dyspnea, post-obstructive pneumonia, and hemoptysis. Surgery for very locally advanced disease is only effective for a limited number of patients and the effects of conventional antitumor therapies, like radiation therapy or chemotherapy, are inconstant and are too delayed in a palliative context. In this review, we aim to provide pulmonologists with an exhaustive technical overview of (I) the bronchoscopic management of benign endobronchial lesions; (II) the bronchoscopic management of malignant tumors, including the curative treatment of localized lesions and palliative management of malignant proximal airway stenosis; and (III) descriptions of the emerging endoscopic techniques used to treat peripheral lung tumors.